Skip to content

Effect of aripiprazole on prevention of delerium

Evaluating the effect of aripiprazole as add on therapy for delirium prophylaxis in patients admitted to the intensive care unit

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017011810178N12
Enrollment
40
Registered
2017-03-06
Start date
2017-01-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium, not induced by alcohol and other psychoactive substances

Interventions

Intervention 1: Intervention: Tablet aripiprazole 15 mg daily orally for seven days. Intervention 2: Control: Tablet placebo once daily for 7 days.
Treatment - Drugs
Placebo
Intervention: Tablet aripiprazole 15 mg daily orally for seven days
Control: Tablet placebo once daily for 7 days

Sponsors

Shahid Beheshti University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18-80 yo patients admitted to intensive care unit Exclusion criteria: pregnancy; breastfeeding; preexisting active delirium; bradycardia (heart rate <60); alcohol intoxication; liver failure (Child Pough Score: sever); kidney failure(GFR<15); history of anti-psychotic drug(s); ICU stay less than 3 days

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Delirium incidence. Timepoint: Entrance to study, Daily for 7 days. Method of measurement: Evaluation of CAM-ICU score.

Secondary

MeasureTime frame
Drug effect on Lipid profile. Timepoint: Day 0 and 7. Method of measurement: Blood sample.;Drug effect on blood sugar. Timepoint: Daily. Method of measurement: Blood sample.;Drug effect on liver function tests. Timepoint: Day 0 and 7. Method of measurement: Blood sample.;Drug effect on ICU stay. Timepoint: Daily. Method of measurement: Counting the Admission days.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Sistanizad

Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences

sistanizadm@sbmu.ac.ir+98 218800087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026